This study examines hybrid coronary revascularization (HCR), a treatment combining minimally invasive coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) for multivessel coronary artery disease (MV CAD). It involved 138 patients who underwent either MIDCAB or MICS-CABG, with a median follow-up of 11 years. Results showed a 36.7% incidence of major adverse cardiac and cerebral events (MACCE) and a higher mean survival rate for those completing hybrid treatment. The study supports HCR as a safe and effective option, highlighting the need for organized PCI steps post-surgery.